IP Library Granted Patent US 7,544,781
Granted Patent B2
US 7,544,781 · App. 11/878,724 · Granted Jun 9, 2009

Polypeptide and process for producing the same

Assignee: PHG Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,544,781
App. No.
11/878,724
Granted
Jun 9, 2009
Kind
B2
Abstract

A process for producing a polypeptide, by reacting a peptide component (A) represented by formula (1) below with a peptide component (B) represented by formula (2) below and optionally a compound (C) represented by formula (3) below, to obtain said polypeptide: (1) X-(Pro-Y-Gly) n -OH, wherein: X represents H or the group HOOC—(CH 2 ) m —CO— and m denotes an integer of 1 to 18, Y represents Pro or Hyp, and n denotes an integer of 1 to 20; (2) X-(Z) r —OH, wherein X represents H or the group HOOC—(CH 2 ) m —CO— and m denotes an integer of 1 to 18, Z represents a peptide chain comprising 1 to 10 amino acid residue(s), and r denotes an integer of 1 to 20; and (3) H 2 N—R—NH 2 , wherein R represents a linear or branched alkylene group; and further wherein the ratio of the peptide component (A) relative to the peptide component (B) is 100/0 to 30/70 (mol %); provided that in the case where X represents the group HOOC—(CH 2 ) m —CO— and m has the same meaning as defined above in formula (1) and/or (2), the amount of compound (C) is substantially 1 mol relative to 1 mol of the total molar amount of peptide component (A) and/or peptide component (B); and in the case where X represents H in the formula (1) and/or (2), the reaction is conducted without compound (C).

Claims (49)

1. A process for producing a polypeptide, which comprises:

reacting a peptide component (A) represented by formula (1) below with a peptide component (B) represented by formula (2) below and optionally a compound (C) represented by formula (3) below, to obtain said polypeptide:

(1) X-(Pro-Y-Gly) n -OH, wherein:

X represents H or the group HOOC—(CH 2 ) m —CO— and m denotes an integer of 1 to 18,

Y represents Pro or Hyp, and

n denotes an integer of 1 to 20;

(2) X-(Z) r -OH, wherein

X represents H or the group HOOC—(CH 2 ) m —CO— and m denotes an integer of 1 to 18,

Z represents a peptide chain comprising 1 to 10 amino acid residue(s), and

r denotes an integer of 1 to 20; and

(3) H 2 N—R—NH 2 , wherein

R represents a linear or branched alkylene group; and

further wherein the ratio of the peptide component (A) relative to the peptide component (B) [the former (A)/the latter (B)] is 100/0 to 30/70 (mol %); provided that

in the case where X represents the group HOOC—(CH 2 ) m —CO— and m has the same meaning as defined above in formula (1) and/or (2), the amount of compound (C) is substantially 1 mol relative to 1 mol of the total molar amount of peptide component (A) and/or peptide component (B); and

in the case where X represents H in the formula (1) and/or (2), the reaction is conducted without compound (C).

2. The process according to claim 1 , wherein at least part of the polypeptide forms a triple helical structure.

3. The process according to claim 1 , wherein n denotes an integer of 1 to 3.

4. The process according to claim 1 , wherein n denotes 1.

5. The process according to claim 1 , wherein the polypeptide shows a peak of the molecular weight in a range not less than 5 kD in the molecular weight distribution in terms of a globular protein by means of an aqueous gel permeation chromatograph.

6. The process according to claim 1 , wherein the reaction is carried out in the presence of a dehydrating and condensing agent and a condensing auxiliary.

7. The process according to claim 6 , wherein the condensing auxiliary comprises at least one member selected from the group consisting of an N-hydroxypolycarboxylic imide, an N-hydroxytriazole, a triazine, and ethyl ester of 2-hydroxyimino-2-cyanoacetic acid.

8. The process according to claim 6 , wherein the amount of the condensing auxiliary is 0.5 to 5 mol relative to the total molar amount of said reaction components (1), (2) and (3).

9. The process according to claim 1 , wherein the reaction is carried out in the presence of at least a dehydrating and condensing agent.

10. The process according to claim 9 , wherein the dehydrating and condensing agent comprises at least one member selected from the group consisting of a carbodiimide-series condensing agent, a fluorophosphate-series condensing agent, and a diphenylphosphorylazide.

11. The process according to claim 9 , which is conducted in a water-free solvent system, wherein the proportion of the dehydrating and condensing agent is 0.7 to 5 mol relative to 1 mol of the total molar amount of said reaction components (1), (2) and (3).

12. The process according to claim 9 which is conducted in a water-containing solvent system, wherein the proportion of the dehydrating and condensing agent is 2 to 500 mol relative to 1 mol of the total molar amount of said reaction components (1), (2) and (3).

13. A polypeptide comprising a peptide unit represented by formula (1) below and optionally one or more units represented by formulae (2) to (3) below:

[—(OC—(CH 2 ) m —CO) p -(Pro-Y-Gly )n -] a   (1);

[—(OC—(CH 2 ) m —CO) q -(Z) r -] b   (2); and

[—HN—R—NH—] c   (3),

wherein “m” denotes an integer of 1 to 18, “p” and “q” are the same or different, each representing 0 or 1, “Y” represents Pro or Hyp, and “n” denotes an integer of 1 to 20; “Z” represents a peptide chain comprising 1 to 10 amino acid residue(s), “r” denotes an integer of 1 to 20, and “R” represents a linear or branched alkylene group; the molar ratio of “a” relative to “b” [a/b] is 100/0 to 30/70;

when p=1 and q=0, c=a,

when p=0 and q=1, c=b,

when p=1 and q=1, c=a+b, and

when p=0 and q=0, c=0; and

wherein the polypeptide shows a peak of molecular weight in a range from 10 kD to 1000 kD in the molecular weight distribution in terms of a globular protein by means of an aqueous gel permeation chromatography.

14. The polypeptide according to claim 13 , wherein “m” denotes an integer of 2 to 12; “n” denotes an integer of 2 to 15; “Z” is a peptide chain comprising at least an amino acid residue or a peptide residue selected from the group consisting of Gly, Sar, Ser, Glu, Asp, Lys, His, Ala, Val, Leu, Arg, Pro, Tyr, and Ile; “r” denotes an integer of 1 to 10; and “R” represents a C 2-12 alkylene group.

15. The polypeptide according to claim 13 , which shows positive Cotton effect at a wavelength in range of 220 to 230 nm and negative Cotton effect at a wavelength in range of 195 to 205 nm in a circular dichroism spectrum.

16. The polypeptide according to claim 13 , wherein at least part of the polypeptide forms a triple helix.

17. The polypeptide according to claim 13 , which is in a form of a solution, a suspension, a particulate, a film or sheet, a fibrous substance, a gelatinous substance, or a sponge-like porous substance.

18. The polypeptide according to claim 13 , which is in a form of a sponge-like porous substance obtained by lyophilization.

19. A biomaterial or biocompatible material comprising the polypeptide according to claim 13 .

20. A cosmetic preparation, which comprises the polypeptide according to claim 13 .

21. A food additive, which comprises the polypeptide according to claim 13 .

22. A composition for use in a pharmaceutical composition, said composition comprising the polypeptide according to claim 13 together with a liquid or solid substrate.

23. A method comprising applying the polypeptide according to claim 13 to a tissue of a subject.

24. A coating agent for coating a surface of a substrate, which comprises the polypeptide according to claim 13 .

25. A medical material comprising the polypeptide according to claim 13 .

26. The medical material according to claim 25 , wherein the medical material is a tissue engineering carrier, a regenerative medical treating carrier, a tissue binding agent, an antiadhesive material, a surgical operating suture, a hemostatic material or a contact lens.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2020
From: JNC CORPORATION
To: UNIQS CORPORATION
Reel/Frame 052035/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2011
From: CHISSO CORPORATION
To: JNC CORPORATION
Reel/Frame 026187/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2009
From: PHG CORPORATION
To: CHISSO CORPORATION
Reel/Frame 022993/0330 →
Priority Claims (1)
JP 2002-53299 · Feb 28, 2002 · national
Continuity (2)
Continuation 1037299400 · Feb 26, 2003
Related Publication 20080009604A1 · Jan 10, 2008